WHO Archives - Page 2 of 3

Home
/
Projects
/

WHO

Global TB vaccine partnership

2011-2023

The Global Tuberculosis Vaccine Partnership (GTBVP) is a forum for key stakeholders in TB vaccine R&D to identify and address barriers impeding TB vaccine R&D and to discuss R&D priorities in order to help inform funding decisions

BCG and new preventive tuberculosis vaccines: Implications for healthcare workers.

2016

BCG revaccination, Hypothetical vaccines

Completed

BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers

New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01E and BCG-revaccination

2023

BCG revaccination, M72/AS01e

Completed

We estimated the potential health and economic impact of M72/AS01E and BCG-revaccination in India and investigated the impact of variation in vaccine characteristics and delivery strategies.

Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis

2022

M72/AS01e

Completed

We conducted expert interviews to identify plausible vaccination implementation strategies for the novel M72/AS01E vaccine candidate. The strategies were defined in terms of target population, coverage, vaccination schedule and delivery mode. We modelled these strategies to estimate long-term resource requirements and health benefits arising from vaccination over 2025–2050.

Is neglect of self-clearance biasing TB vaccine impact estimates?

2023

Hypothetical vaccines

Completed

exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India

The full value of vaccine assessments concept—current opportunities and recommendations

2024

Completed

Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.

Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report

2024

Completed

A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.

Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes

2019

Completed

The preferred product characteristics (PPC) for therapeutic TB vaccines described in this document are intended to provide guidance to scientists, funding agencies, public and private sector organizations developing such vaccine candidates. This document presents potential clinical end-points for ev idence generation and discusses key considerations about potential clinical development strategies

The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study

2023

Hypothetical vaccines

Completed

We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study

2023

Hypothetical vaccines

Completed

We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.